Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Last trade$9.04
Day change-$0.24 (-2.59%)
Day range$8.56 – $9.58
Volume529,390
Market cap$240M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$239.83M
Price / earnings
—
Price / book
1.49×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.04×
Profitability
Earnings per share
-$8.18
Return on assets
-118.11%
Return on equity
-131.2%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.12×
Quick ratio
16.12×
Cash ratio
1.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FTH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$10.35M
$9.21M
Research and development
$11.74M
$9.18M
Total operating expenses
$22.09M
$18.39M
Operating income
-$22.09M
-$18.39M
Interest expense
$0
$0
Income before taxes
-$20.4M
-$16.01M
Income taxes
$0
$0
Net income
-$20.4M
-$16.01M
Net income attributable to common shareholders
-$20.4M
-$16.01M
EBITDA
-$22.07M
-$18.36M
Basic earnings per share
-$0.79
-$2.84
Diluted earnings per share
-$0.79
-$2.84
Recent news
Company coverage with links to the original publishers.
DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.